-+ 0.00%
-+ 0.00%
-+ 0.00%

Eli Lilly Says Phase 3 Study Shows BMI Reduction in Adolescents on Zepbound

MT Newswires·11/16/2026 00:25:05
Listen to the news
12:25 AM EST, 11/16/2026 (MT Newswires) -- Eli Lilly (LLY.SW, LLY.F) reported that Zepbound, or tirzepatide, helped reduce the body mass index of adolescents with obesity by 21.4%, on average. The pharmaceutical company said Nov. 14 that results of the phase 3 trial for the weight-loss medication in patients aged 12 years to less than 18 years will be presented, along with other updates from its cardiometabolic health portfolio, at ObesityWeek 2026, which is being held in Washington, D.C., in the US, from Nov. 14 through Tuesday. Zepbound is indicated for adults with obesity and is also approved in the US as a treatment for adults with moderate-to-severe obstructive sleep apnea and obesity. The ongoing phase 3 study is looking at a potential expansion of the indication for the medication to include adolescents.